Otonomy begins OTO-313 Phase 1/2 clinical study for tinnitus patients
Category: #health  By Mateen Dalal  Date: 2019-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Otonomy begins OTO-313 Phase 1/2 clinical study for tinnitus patients

Results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development

Biopharmaceutical firm Otonomy, Inc., has reportedly initiated the Phase 1/2 clinical trial of OTO-313 in patients suffering from tinnitus. OTO-313, apparently, is a sustained-exposure formulation of gacyclidine, the NMDA receptor antagonist.

The Phase 1/2 study, which is double-blind, randomized and placebo-controlled, would consist of an initial safety cohort to be followed by an exploratory study of efficacy, enrolling nearly 50 patients having subjective tinnitus, Otonomy confirmed.

Otologist and Neurotologist at the Ear Medical Group in San Antonio and a University of Texas Health Science Center clinical professor, Susan Marenda King, M.D., said that tinnitus has become a common issue that affects millions of people.

The disorder can lead to constant annoyance which negatively impacts the quality of life of a person, by disrupting their concentration and the ability to enjoy leisurely activities or obtain sufficient sleep, Dr. Susan added. She also mentioned that presently, there is no drug therapy for treating these patients.

President and CEO of Otonomy, David A. Weber, Ph.D., stated that this trial of OTO-313 would be evaluating its potential as a therapy for patients with tinnitus. He informed that results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development.

Supposedly, a Phase 1 clinical safety trial had been completed earlier for an initial formulation of gacyclidine, where no safety concerns were observed. OTO-313 is considered as an enhanced formulation of gacyclidine and a single intratympanic injection is to be used for its administration.

For the uninitiated, tinnitus is the medical term used when a person experiences the perception of noise even when there is no sound. Patients often described it as a ringing in the ear, but it can also sound like clicking, roaring, buzzing or hissing. Estimates show that nearly 10% of U.S. adults are living with this condition.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

FreightCar America forms new railcar production JV with Fasemex
FreightCar America forms new railcar production JV with Fasemex
By Mateen Dalal

Despite ongoing geopolitical tensions, Mexico is still the primary trading partner for the United States. Owing to the wide-scale presence of skilled and affordable workforce, Mexico is ideal for enterprises looking to optimize operations and attain ...

Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
Knopp posts data of KB-3061 working on KCNQ2 Epileptic Encephalopathy
By Mateen Dalal

KCNQ2 epileptic encephalopathies is a serious type of neonatal epileptic condition which manifests in newborn children during the first week if their lives. This disease is being addressed by various pharmaceutical companies across the globe trying t...

Novo Nordisk and Medtronic team up to offer digital diabetes solutions
Novo Nordisk and Medtronic team up to offer digital diabetes solutions
By Mateen Dalal

With growing population of diabetic patients, diabetes management is becoming a daunting activity. Sugar level management and insulin injections tracking is a difficult work. Thus, leading pharmaceutical companies are collaborating with medical devic...